Skip to main content

Table 3 Summary of microorganism safety of human deciduous pulp stem cell products

From: A model study for the manufacture and validation of clinical-grade deciduous dental pulp stem cells for chronic liver fibrosis treatment

Donor

Endotoxin (EU)

FTA-ABS

Mycoplasma

HCV

HBV

HTLV-1

Parbovirus

CMV

HIV-1

P3

 #1

0.025

–

–

–

–

–

–

–

–

 #2

0.021

–

–

–

–

–

–

–

–

 #3

0.023

–

–

–

–

–

–

–

–

 #4

0.022

–

–

–

–

–

–

–

–

 #5

0.025

–

–

–

–

–

–

–

–

 #6

0.027

–

–

–

–

–

–

–

–

 #7

0.023

–

–

–

–

–

–

–

–

 #8

0.023

–

–

–

–

–

–

–

–

 #9

0.022

–

–

–

–

–

–

–

–

 #10

0.025

–

–

–

–

–

–

–

–

P10

 #1

0.024

–

–

–

–

–

–

–

–

 #2

0.023

–

–

–

–

–

–

–

–

 #3

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 #4

0.026

–

–

–

–

–

–

–

–

 #5

0.023

–

–

–

–

–

–

–

–

 #6

0.025

–

–

–

–

–

–

–

–

 #7

0.024

–

–

–

–

–

–

–

–

 #8

0.025

–

–

–

–

–

–

–

–

 #9

0.021

–

–

–

–

–

–

–

–

 #10

0.027

–

–

–

–

–

–

–

–

Thawed-P10

 #2

0.023

–

–

–

–

–

–

–

–

 #10

0.024

–

–

–

–

–

–

–

–

  1. P3 passage 3 human deciduous pulp stem cell products, P10 passage 10 human deciduous pulp stem cell products, Thawed-P10 Thawed-P10 human deciduous pulp stem cell products, CMV cytomegalovirus, FTA-ABS fluorescent treponemal antibody absorption test, HBV hepatitis B virus, HCV hepatitis C virus, HIV-1 human immunodeficiency virus type 1, HTLV-1 human T-cell leukemia virus type 1